BioSpace News Archive

Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced financial results for the first quarter of fiscal 2023, which ended September 30, 2022.

Incyte (Nasdaq:INCY) today reports 2022 third quarter financial results, and provides a status update on the Company’s clinical development portfolio.

Voyager Therapeutics, Inc. today announced it will report third quarter 2022 financial and operating results before the market opens on Tuesday, November 8, 2022.

Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its third quarter 2022 financial results will be released after market close on Tuesday, November 8th, 2022.

Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, today announced that it will share five scientific presentations at The Liver Meeting™ 2022, hosted by the American Association for the Study of Liver Diseases (AASLD), to be held November 4-8, 2022, in Washington, D.C.

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) announces that Evan Loh, M.D., chief executive officer, will present at the Credit Suisse 31st Annual Healthcare Conference held Nov. 7-10.

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it will report third quarter 2022 financial results on Tuesday, November 8, 2022, after the close of U.S. markets.

Frontier Medicines Corporation announced that Chris Varma, Ph.D., Frontier’s co-founder, chairman, and CEO, will participate in a fireside chat at the Credit Suisse 31st Annual Healthcare Conference at 9:10 a.m. PT on November 8, 2022 in Rancho Palos Verdes, CA.

Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced the appointment of Margaret Fitzgerald as Chief Legal Officer and General Counsel, effective immediately.

AltruBio Inc. announced that AltruBio President and CEO Judy Chou, Ph.D., has been appointed to the Independent Citizens’ Oversight Committee, the governing Board of the California Institute for Regenerative Medicine.